Day One Biopharmaceutical... (DAWN)
| Bid | 8.29 |
| Market Cap | 842.26M |
| Revenue (ttm) | 141.99M |
| Net Income (ttm) | -103.38M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -8.15 |
| Forward PE | -11.55 |
| Analyst | Buy |
| Ask | 8.47 |
| Volume | 570,861 |
| Avg. Volume (20D) | 1,188,905 |
| Open | 8.19 |
| Previous Close | 8.23 |
| Day's Range | 8.12 - 8.44 |
| 52-Week Range | 7.88 - 18.07 |
| Beta | -1.39 |
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral s...
Analyst Forecast
According to 7 analyst ratings, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 309.15% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendi...
2 months ago · seekingalpha.com
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has signi...
